• 665
  • 0
orpyx-review
walk-a-mile

Meet the SurroSense Rx™

Orpyx will be attending theAPMA Annual Scientific Meetingin Las Vegas from July 21-25th where we will be launching theSurroSense Rx™ device.  For the first time ever, people will be able to sign out trial devices at the show.  We are encouraging all attendees to lace up, walk a mile in our shoes, and see the potential for the SurroSense Rx™ device to truly make a difference in the lives of those living with peripheral neuropathy

Hot to Trot

We are thrilled to announce that Orpyx's flagship product, the SurroSense Rx™ device, will be available in select US clinics as of Fall 2013.  Things are abuzz at the Orpyx HQ, as we implement our ISO:13485 Quality System, prepare our medical device assembly space, and hit "go" on our initial product order.  Beyond these commercialization-focused efforts, we continue to hone in on a number of key areas, including further research and development, intellectual property portfolio expansion and international distribution planning.  Orpyx is working towards establishing global distribution opportunities outside of North America, with a focus on the UAE, Australia, Japan and the EU.  The company continues to be a focus of attention for worldwide leaders in the medical device and wound care spaces.

From a trial perspective, the manuscript detailing our Proof of Principle and Calibration studies on the SurroSense Rx™ system, Validation of Plantar Pressure Measurements for a Novel In-Shoe Plantar Sensory Replacement Unit, has been accepted for publication in the Journal of Diabetes Science and Technology this coming September.  We are proud of the work that Dr. Reed Ferber and the University of Calgary's Running Injury Clinic have done in producing this work.  Data collection for Pilot studies on the SurroSense Rx™ and SurroGait Rx™ systems continue under the leadership of of Dr. David Armstrong (SALSA, University of Arizona) and Dr. Benno Nigg / Dr. Cory Toth (Human Performance Lab, University of Calgary), respectively.  We expect to have interim data for both these studies later this summer.  We are enthused to announce partnership with Dr. Andrew Boulton's team out of the University of Manchester and the Manchester Metropolitan University; Dr. Boulton's group will be engaging in a large, Randomized Control Trial investigating the clinical and pharmacoeconomic effectiveness of the SurroSense Rx™device.  Stay tuned to our website for continued updates!

The Orpyx team continues to grow, as we bring on some of the best and brightest in the field.  We are elated to welcome Travis Stevens, MSc PEng, as our VP Engineering and Daryl Coutts as a Software Engineer.

primary-referral

Primary Care Referral Program

Also, at the APMA conferencewe will be signing up select clinics to become a part of our Primary Care Referral Program.  The program is an opportunity for select podiatry clinics to become exclusive retailers of SurroSense Rx™ devices and help transform the way we address peripheral neuropathyand its associated complications.  Help your patients feel their feet again!  Contact us for more info.

plastic-surgery-foundation

Big Win for Orpyx at TIPS

Orpyx was awarded with top honours for the best new technological advancement at the inaugural TIPS Innovation Challenge.  The goal of the challenge is to foster development of the best new technology and innovations in the field of cosmetic and reconstructive surgery.  Dr. Everett has been asked to come to Chicago later this month to do a talk for the Plastic Surgery Foundation in Chicago.

converge

Orpyx at CONVERGE

Earlier this month Dr. Everett was asked to speak on the"Diabetes Re-Boot" panel at theCONVERGE Summit in Philadelphia.  She was joined alongside respected industry leaders to discuss promising innovations in healthcare specific to diabetes.   CONVERGE gathers decision makers from every sector to debate the challenges and opportunities facing the industry.  See media coverage from the event here.

Copyright © 2013 Orpyx Medical Technologies Inc., All rights reserved. 
You are receiving this e-mail because you opted in at our websitewww.orpyx.com
Our mailing address is: 

Orpyx Medical Technologies Inc.

214-1235 26th Avenue SE

Calgary, Alberta T2G 1R7

Canada

Add us to your address book

Email Marketing Powered by MailChimp

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.

Add Comment